Phase 1 · Understand the Body — Why the disease behaves the way it does.
The One-Line Truth
The whole disease in one chain
Everything on this page exists to explain this line.
Dopamine-making cells in the substantia nigra (the brain's movement-control station) are dying, so your body loses the chemical signal it needs to start and smooth out movement.
A dimming power grid losing its main generator
Imagine a city's electrical grid where the power plant (substantia nigra) sends electricity (dopamine) through main lines (axons) to a distribution hub (striatum) that tells neighborhoods (motor cortex and muscles) when to turn on the lights and how bright. The power plant has automatic backup systems—if one generator breaks, the remaining ones work overtime and grow extra connection lines to keep the city lit. But if the generators keep failing from internal rust and corrosion (alpha-synuclein clumps damaging mitochondria), eventually no amount of overtime can compensate. Once 60–80% of the generators are gone, the voltage crashes. Now neighborhoods get confusing, flickering signals: some lights stutter on and off (tremor), others lock in place at full brightness (rigidity), and new lights take forever to turn on (bradykinesia). The backup systems try to reroute power through slower, less reliable lines (cerebellum), making everything sluggish and effortful. The distribution hub's control switches also wear out from the constant strain (receptor upregulation becomes a liability), so when the city finally gets a power surge from medication, the lights flicker wildly (dyskinesias). Meanwhile, the rust spreading to other parts of the plant (Lewy bodies spreading to olfactory bulb, brainstem, cortex) also breaks the water treatment system (smell), the traffic lights (gait), the hospital backup power (autonomic control), and eventually the city's entire information network (cognition).
Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson Disease 2015 · American Academy of Neurology (AAN) Parkinson Disease Practice Guideline 2023 · National Institute of Neurological Disorders and Stroke (NINDS) · Cochrane systematic reviews on Parkinson Disease · reviewed 2026-07-07